BioStem Technologies (OTC: BSEM)
Tom Dugan is a seasoned executive with extensive experience in the medical device and healthcare industries, currently serving as Chairman of the Board of Directors at BioStem Technologies since December 2023. As a Partner at 360 Life Sciences Advisors, LLC since 2018, Tom Dugan focuses on strategic and operational assessments for acquisitions and investments, as well as business transformation for enhanced performance. Previous roles include President of Integrum AB in the U.S. from 2021 to 2023, where Tom Dugan oversaw the OPRA™ Implant System, along with significant positions such as CEO at Amniox Medical, President at SURGIQUEST during its acquisition by CONMED, and leadership roles at Smith & Nephew, SonoSite, and Covidien. Tom Dugan's career highlights a strong track record of driving growth and innovation within the medical sector.
This person is not in any teams
BioStem Technologies (OTC: BSEM)
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE, VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.